We are live on ! Find out more
XPH icon

State Street SPDR S&P Pharmaceuticals ETF
XPH

59 hedge funds and large institutions have $218M invested in State Street SPDR S&P Pharmaceuticals ETF in 2013 Q2 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

92.26% more ownership

Funds ownership: 0% → 92.26% (+92%)

Holders
59
Holders Change
+59
Holders Change %
–
% of All Funds
1.92%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.1%
New
59
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

XPH Hedge Fund Activity: Q2 2013 in Review

59 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2013, worth a combined $218M.

Buyers outnumbered sellers: 59 funds opened new XPH positions and 0 closed out — a net gain of 59 holders — while 0 added to existing stakes and 0 trimmed.

  • 59 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $218M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2013.
  • 59 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2013 and 0 closed out, a net change of +59 holders.

Based on aggregated 13F filings for Q2 2013.